军事医学2023，Vol.47Issue(12)：942-946,5.DOI:10.7644/j.issn.1674-9960.2023.12.010
41例套细胞淋巴瘤患者临床特点及预后因素分析
Clinical characteristics and prognostic factors of 41 patients with mantle cell lymphoma
摘要
Abstract
Objective To analyze the clinical characteristics,treatment regimens and influencing factors of prognosis of patients with mantle cell lymphoma(MCL).Methods The clinical data of 41 patients with MCL was collected.These patients were initially diagnosed and treated in the Fifth Medical Center of Chinese PLA General Hospital between August 2004 and December 2019.The clinical features,therapeutic efficacy and prognosis-related factors were clarified.Results The median duration of follow-up was 68(1-165)months.The 3-year progression free survival(PFS)and overall survival(OS)were 37.29%and 62.75%respectively.Based on univariate analysis,B symptoms,Eastern Cooperative Oncology Group(ECOG)scores,the mantle cell lymphoma international prognostic index(MIPI),relapse and refractory state and the therapeutic effect were statistically significant for progression free survival.B symptoms,R-chemotherapy and therapeutic effect were statistically significant for overall survival.In multivariate analysis,B symptoms and the MIPI were statistically significant for progression free survival.B symptoms,R-chemotherapy and therapeutic effect were statistically significant for overall survival.There were statistically significant differences in 3-year OS between patients with different MIPI and MIPI-C scores.Conclusion Mantle cell lymphoma mostly occurs in elder males,and is more likely to be detected in late the stage.B symptoms,R-chemotherapy and therapeutic effect are independent prognostic factors for patients with MCL.The MIPI and MIPI-C scores have clinical guidance significance for patient survival.关键词
套细胞淋巴瘤/利妥昔单抗/临床研究/预后Key words
mantle-cell lymphoma/rituximab/clinical study/prognosis分类
临床医学引用本文复制引用
赵世华,杨秋实,陈喜林,肖秀斌..41例套细胞淋巴瘤患者临床特点及预后因素分析[J].军事医学,2023,47(12):942-946,5.基金项目
首都临床特色应用研究项目(Z151100004015006) （Z151100004015006）
